Why Bank of Queensland, Fisher & Paykel, Mayne Pharma, and Medibank Shares Are Rising
Why Bank of Queensland, Fisher & Paykel, Mayne Pharma, and Medibank Shares Are Rising
The Fisher & Paykel Healthcare share price is up 11% to $32.58. Investors have been buying the medical device company's shares following the release of a guidance update this morning. Fisher & Paykel Healthcare is now expecting its revenue to be between NZ$940 million and NZ$950 million for the first half of FY 2015. The mid-point of this range will be an 18% increase over the prior corresponding period. Management expects this to lead to net profit coming in 44% higher at NZ$150 million to NZ$160 million. It notes that "the year to date has begun strongly across all products and regions."In afternoon trade, the $S&P/ASX 200 (.XJO.AU)$ is on course to end its winning streak with a small decline. At the time of writing, the benchmark index is down 0.1% to 8,016.4 points.
下午交易時，該$S&P/ASX 200 (.XJO.AU)$ 指數即將結束連勝，略微下跌。撰寫時，基準指數下跌0.1%，至8016.4點。
Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising today:
以下列出了四種ASX股票，它們不被持有者拖後腿。以下是它們今天上漲的原因:
The Bank of Queensland share price is up 3% to $6.13. This morning, analysts at Morgans responded positively to news that the bank is restructuring its retail operations. The broker sees positives from the restructure and has upgraded its earnings per share estimates to reflect this. As a result, it has upgraded the regional bank's shares to a hold rating with an improved price target of $6.18.
昆士蘭銀行股價上漲3%，至6.13美元。今早，摩根大通的分析師對該銀行重組零售業務的消息做出積極回應。經紀人認爲重組帶來了積極影響，並已調高了每股收益的預計值以反映這一點。因此，他們將該區域銀行的股票評級提升至持有，並提高了其改良後的目標股價至6.18美元。
The Fisher & Paykel Healthcare share price is up 11% to $32.58. Investors have been buying the medical device company's shares following the release of a guidance update this morning. Fisher & Paykel Healthcare is now expecting its revenue to be between NZ$940 million and NZ$950 million for the first half of FY 2015. The mid-point of this range will be an 18% increase over the prior corresponding period. Management expects this to lead to net profit coming in 44% higher at NZ$150 million to NZ$160 million. It notes that "the year to date has begun strongly across all products and regions."
Fisher & Paykel Healthcare股價上漲11%，至32.58美元。投資者在今天上午發佈的指引更新後購買了這家醫療器械公司的股票。Fisher & Paykel Healthcare預計其2015財年上半年的營業收入將在NZ$94000萬至NZ$95000萬之間。這一區間的中點將比去年同期增長18%。管理層預計這將使淨利潤增長44%，達到NZ$15000萬至NZ$16000萬。公司指出，「今年迄今爲止，在所有產品和區域都有良好的開局。」
The Mayne Pharma share price is up almost 10% to $4.32. This follows the release of the pharmaceutical company's full year results. Investors appear impressed with the company's significantly improved performance. Mayne Pharma reported revenue up 112% on the prior corresponding period to $388.4 million and gross profit up 162% to $218.8 million. CEO Shawn Patrick O'Brien said "Mayne Pharma has delivered a significant improvement in Group performance, achieving all five key operating metrics including a positive direct contribution from all three business segments and a positive underlying EBITDA in FY24."
Mayne Pharma股價上漲近10%，至4.32美元。這是繼製藥公司發佈全年業績後的反應。投資者對該公司的表現大爲印象深刻。Mayne Pharma報告的營業收入環比增長112%，達到38840萬美元，毛利潤環比增長162%，達到21880萬美元。首席執行官Shawn Patrick O'Brien表示：「Mayne Pharma集團業績有了顯著改善，實現了五個關鍵運營指標，包括所有三個業務部門的正面直接貢獻和正面的基本盈利與折舊前利潤。」
The Medibank Private share price is up 3% to $3.94. This may have been driven by a broker note out of UBS this morning. In response to the private health insurer's FY 2024 results, the broker has retained its buy rating with an improved price target of $4.30. UBS was pleased with the results and its claims guidance for the year ahead. In light of this, it continues to see plenty of value in its shares at current levels.
Medibank Private股價上漲3%，至3.94美元。這可能是受到UBS今天發佈的經紀商報告的影響。針對該私人醫療保險公司2024財年的業績，這家經紀商保持了其買入評級，並將其目標股價上調至4.30美元。UBS對這一業績以及未來一年的索賠指引表示滿意。鑑於此，它繼續看好該股在目前水平上的價值。